7-Hydroxy-benzopyran-4-one derivatives: A novel pharmacophore of peroxisome proliferator-activated receptor α and -γ (PPARα and γ) dual agonists

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6835-6850

  Matin, Azadeh ^a   Gavande, Navnath ^a   Kim, Moon S ^a   Yang, Nancy X ^a   Salam, Noeris K ^a,b   Hanrahan, Jane R ^a   Roubin, Rebecca H ^a   Hibbs, David E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SCHRÖDINGER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3' METHOXY 7 HYDROXYISOFLAVONE; 3',4' METHYLENEDIOXY 7 HYDROXYISOFLAVONE; 4' FLUORO 7 HYDROXYISOFLAVONE; 7 HYDROXY BENZOPYRAN 4 ONE DERIVATIVE; CHALCONE; DRUG STRUC3',5' DIMETHOXY 7 HYDROYISOFLAVONE; FIBRIC ACID DERIVATIVE; FLAVANONE DERIVATIVE; ISOFLAVONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS;

BENZOPYRANS; CELL LINE; HUMANS; PPAR ALPHA; PPAR GAMMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049127438     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900964r     Document Type: Article

References (41)

1. Salam, N. K.; Huang, T. H. W.; Kota, B. P.; Kim, M. S.; Li, Y.; Hibbs, D. E. Novel PPAR gamma agonists identified from a natural product library: A virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 2008, 71, 57-70.
2. Chiarelli, F.; Marzio, D. D. Peroxisome proliferator-activated receptor gamma agonists and diabetes: current evidence and future perspectives. Vasc. Health Risk Manage. 2008, 4, 297-304.
3. Nobuo, C.; Yu, M. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: From the discovery to recent progress. Curr. Top. Med. Chem. 2008, 8, 1483-1507.
4. Tenenbaum, A.; Motro, M.; Fisman, E. Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc. Diabetol. 2005, 4, 14.
5. Nehlin, J. O.; Mogensen, J. P.; Petterson, I.; Jeppesen, L.; Fleckner, J.; Wulff, E. M.; Sauerberg, P. Selective PPAR agonists for the treatment of type 2 diabetes. Ann. N.Y. Acad. Sci. 2006, 1067, 448-453.
6. Khoo, B. Y.; Najimudin Nazalan Muhammad; Tengku, T. S. The PPAR gamma coding region and its role in visceral obesity. Biochem. Biophys. Res. Commun. 2008, 371, 177-179.
7. Chakrabarti, R.; Rajagopalan, R. The role of PPARs in obesity and other insulin resistance associated disorders. Curr. Med. Chem: Immunol. Endocr. Metab. Agents 2004, 4, 67-73.
8. Villacorta, L.; Schopfer, F. J.; Zhang, J.; Freeman, B. A.; Chen, E. Y. PPAR gamma and its ligands: therapeutic implications in cardiovascular disease. Clin. Sci. 2009, 116, 205-218.
9. Burton, J. D.; Goldenberg, D. M.; Blumenthal, R. D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008, 2008, 494161.
10. Kostadinova, R.; Wahli, W.; Michalik, L. PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem. 2005, 12, 2995-3009.
11. Landreth, G.; Jiang, Q.; Mandrekar, S.; Heneka, M.PPARgamma agonists as therapeutics for the treatment of Alzheimer0s disease. Neurotherapeutics 2008, 5, 481-489.
12. Pastromas, S.; Sakellariou, D.; Koulouris, S. Thiazolidinediones anti-inflammatory and anti-atherosclerotic effects in type 2 diabetes mellitus. Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2008, 7, 217-223.
13. Rodrigo, M.-C.; Poblete, B. M.; Gonzalez, G. O.; Leiva, M. E.; Mujica, E. V.; Aranguez, A. C.; Ivan, P. Peroxisome proliferator-activated receptors: targets for the treatment of metabolic illnesses (review). Mol. Med. Rep. 2008, 1, 317-324.
14. Ahmed, I.; Furlong, K.; Flood, J.; Treat, V. P.; Goldstein, B. J. Dual PPAR alpha and gamma agonists: promises and pitfalls in type 2 diabetes. Am. J. Ther. 2007, 14, 49-62.
15. Pingali, H.; Jain, M.; Shah, S.; Makadia, P.; Zaware, P.; Goel, A.; Patel, M.; Giri, S.; Patel, H.; Patel, P. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha and gamma dual agonists. Bioorg. Med. Chem. 2008, 16, 7117-7127.
16. Santilli, A. A.; Scotese, A. C.; Tomarelli, R. M. A Potent Antihypercholesterolemic Agent: [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic Acid (WY-14643). Experientia 1974, 30, 1110-1111.
17. Yang, T.; Soodvilai, S. Renal and vascular mechanisms of thiazolidinedione- induced fluid retention. PPAR Res. 2008, 2008, 943614.
18. Spiegelman, B. M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47, 507-514
19. Kohen, F.; Gayer, B.; Kulik, T.; Frydman, V.; Nevo, N.; Katzburg, S.; Limor, R.; Sharon, O.; Stern, N.; Somjen, D. Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Boc-hexylenediamine. J. Med. Chem. 2007, 50, 6405-6410.
20. Blank, V. C.; Poli, C.; Marder, M.; Roguin, L. P. Antiproliferative activity of various flavonoids and related compounds: additive effect of interferon-α2b. Bioorg. Med. Chem. Lett. 2004, 14, 133-136.
21. Bozdaǧ-Dundar, O. B.; Verspohl, E. J.; Daş-Evcimen, N.; Kaup, R. M.; Bauer, K.; Saríkaya, M.; Evranos, B.; Ertan, R. Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg. Med. Chem. 2008, 16, 6747-6751.
22. Li, X.-C.; Joshi, A. S.; ElSohly, H. N.; Khan, S. I.; Jacob, M. R.; Zhang, Z.; Khan, I. A.; Ferreira, D.; Walker, L. A.; Broedel, S. E.; Raulli, R. E.; Cihlar, R. L. Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies. J. Nat. Prod. 2002, 65, 1909-1914.
23. Arthan, D.; Svasti, J.; Kittakoop, P.; Pittayakhachonwut, D.; Tanticharoen, M.; Thebtaranonth, Y. Antiviral isoflavonoid sulfate and steroidal glycosides from the fruits of Solanum torvum. Phytochemistry 2002, 59, 459-463. (Pubitemid 34202567)
24. Laupattarakasem, P.; Houghton, P. J.; Robin, J.; Hoult, S. Antiinflammatory isoflavonoids from the stems of Derris scandens. Planta Med. 2004, 70, 496-501.
25. Kang, K. A.; Zhang, R.; Piao, M. J.; Ko, D. O.; Wang, Z. H.; Kim, B. J.; Park, J. W.; Kim, H. S.; Kim, D. H.; Hyun, J. W. Protective effect of irisolidone, a metabolite of kakkalide, against hydrogen peroxide induced cell damage via antioxidant effect. Bioorg. Med. Chem. 2008, 16, 1133-1141.
26. Qin, C. H.; Chen, X.; Hughes, R. A.; Williams, S. J.; Woodman, O. L. Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity. J. Med. Chem. 2007, 51, 1874-1884.
27. Kim, Y.-W.; Mobley, J. A.; Brueggemeier, R. W. Synthesis and estrogen receptor binding affnities of 7-hydroxy- 3-(4-hydroxyphenyl)- 4H-1-benzopyran-4-ones containing a basic side chain. Bioorg. Med. Chem. Lett. 2003, 13, 1475-1478.
28. Kim, Y.-W.; Hackett, J. C.; Brueggemeier, R. W. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem. 2004, 47, 4032-4040.
29. Tadigoppula, N.; Shweta, G. S. A convenient and biogenetic type synthesis of few naturally occurring chromeno dihydrochalcones and their in vitro antileishmanial activity. Bioorg. Med. Chem. Lett. 2004, 14, 3913-3916.
30. Felpin, F. X.; Lory, C.; Sow, H.; Acherar, S. Practical and efficient entry to isoflavones by Pd(0)/C-mediated Suzuki-Miyaura reaction. Total synthesis of geranylated isoflavones. Tetrahedron 2007, 63, 3010-3016.
31. Menichincheri, M.; Ballinari, D.; Bargiotti, A.; Bonomini, L.; Ceccarelli,W.; D'Alessio, R.; Fretta, A.;Moll, J.; Polucci, P.; Soncini, C.; Tibolla,M.; Trosset, J. Y.; Vanotti, E. Catecholic flavonoids acting as telomerase inhibitors. J. Med. Chem. 2004, 47, 6466-6475.
32. Vasquez-Martinez, Y.; Ohri, R. V.; Kenyon, V.; Holmanb, T. R.; Sepúlveda-Bozaa, S. Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg. Med. Chem. 2007, 15, 7408-7425.
33. Kim, Y. W.; Brueggemeier, R. W. A convenient one-pot synthesis of 2-alkylthio isoflavones from deoxybenzoins using a phase transfer catalyst. Tetrahedron Lett. 2002, 43, 6113-6115.
34. Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, S.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48, 4212-4215.
35. Bramlett, K. S.; Houck, K. A.; Borchert, K. M.; Dowless, M. S.; Kulanthaivel, P.; Zhang, Y.; Beyer, T. P.; Schmidt, R.; Thomas, J. S.; Michael, L. F.; Barr, R.; Montrose, C.; Eacho, P. I.; Cao, G.; Burris, T. P. A natural product ligand of the oxysterol receptor, liver X receptor. J. Pharmacol. Exp. Ther. 2003, 307, 291-296.
36. Jung, S. H.; Park, S. Y.; Kim-Pak, Y.; Lee, H. K.; Park, K. S.; Shin, K. H.; Ohuchi, K.; Shin, H.-K.; Keum, S. R.; Lim, S. S. Synthesis and PPAR-gamma ligand-binding activity of the new series of 2́-hydroxychalcone and thiazolidinedione derivatives. Chem. Pharm. Bull. 2006, 54, 368-371.
37. Liang, Y.-C.; Tsai, S.-H.; Tsai, D.-C.; Lin-Shiau, S.-Y.; Lin, J.-K. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptorgamma by flavonoids in mouse macrophages. FEBS Lett. 2001, 496, 12-18.
38. Chacko, B. K.; Chandler, R. T.; D'Alessandro, T. L.; Mundhekar, A.; Khoo, N. K. H.; Botting, N.; Barnes, S.; Patel, R. P. Antiinflammatory effects of isoflavones are dependent on flow and human endothelial cell PPAR gamma. J. Nutr. 2007, 137, 351-356.
39. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J.F.; Mook, R. A.; Noble, S. A.; Oliver, W.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
40. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527-550.
41. Guo, L.; Hu, W.-R.; Lian, J.-H.; Ji, W.; Deng, T.; Qian, M.; Gong, B.-Q. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. Eur. J. Pharmacol. 2006, 551, 80-86.